Dengue vaccines: progress and challenges.

With several dengue vaccine candidates progressing through clinical trials, several options for controlling this disease appear feasible. This would represent a major achievement and reflect decades of research and development activities. The challenges associated with the limited understanding of protective responses and those factors which determine disease severity remain, but with prospective studies ongoing in various dengue endemic areas and the initiation of dengue vaccine efficacy trials, immune responses are being evaluated in the context of protection and severe disease and these studies are highly likely to provide additional insights.

[1]  Gregory D. Gromowski,et al.  Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. , 2010, Virology.

[2]  B. Murphy,et al.  rDEN2/4Δ30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Naïve Adults , 2006, Human vaccines.

[3]  Rosanna W. Peeling,et al.  Dengue: a continuing global threat , 2010, Nature Reviews Microbiology.

[4]  S. Halstead Dengue in the Americas and Southeast Asia: do they differ? , 2006, Revista panamericana de salud publica = Pan American journal of public health.

[5]  Tao Dong,et al.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever , 2003, Nature Medicine.

[6]  A. Nisalak,et al.  Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. , 2008, The American journal of tropical medicine and hygiene.

[7]  Brian R. Murphy,et al.  Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys , 2005, Journal of Virology.

[8]  Prida Malasit,et al.  Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010, Science.

[9]  B. Murphy,et al.  Development of a live attenuated dengue virus vaccine using reverse genetics. , 2006, Viral immunology.

[10]  J. Lang Recent progress on sanofi pasteur's dengue vaccine candidate. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  S. Halstead Antibodies Determine Virulence in Dengue , 2009, Annals of the New York Academy of Sciences.

[12]  D. Vaughn,et al.  Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults , 2009, Human vaccines.

[13]  M. Guzmán,et al.  Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. , 2010, The American journal of tropical medicine and hygiene.

[14]  S. Halstead,et al.  Dengue , 1872, The Lancet.

[15]  A. Rothman T Lymphocyte Responses to Heterologous Secondary Dengue Virus Infections , 2009, Annals of the New York Academy of Sciences.

[16]  A. Fauci,et al.  Dengue and hemorrhagic fever: a potential threat to public health in the United States. , 2008, JAMA.

[17]  B. Guy,et al.  Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). , 2006, Vaccine.

[18]  S. Halstead,et al.  Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. , 2001, The American journal of tropical medicine and hygiene.

[19]  A. Nisalak,et al.  Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. , 2005, The Journal of infectious diseases.

[20]  Gregory D. Gromowski,et al.  Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes , 2007, Journal of Virology.

[21]  D. Gubler The global emergence/resurgence of arboviral diseases as public health problems. , 2002, Archives of medical research.

[22]  T. Scott,et al.  Consequences of the Expanding Global Distribution of Aedes albopictus for Dengue Virus Transmission , 2010, PLoS neglected tropical diseases.

[23]  C. Nelson,et al.  The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 , 2010, PLoS pathogens.

[24]  B. Guy,et al.  Development of sanofi pasteur tetravalent dengue vaccine , 2010, Human vaccines.

[25]  Cameron P Simmons,et al.  The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. , 2010, Cell host & microbe.

[26]  M. Guzmán,et al.  The epidemiology of dengue in the americas over the last three decades: a worrisome reality. , 2010, The American journal of tropical medicine and hygiene.

[27]  R. Jarman,et al.  A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model , 2009, PLoS medicine.

[28]  G. Perng,et al.  A Re‐evaluation of the Mechanisms Leading to Dengue Hemorrhagic Fever , 2009, Annals of the New York Academy of Sciences.

[29]  B. Murphy,et al.  The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers , 2006, Human vaccines.

[30]  B. McKinney,et al.  Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. , 2009, The American journal of tropical medicine and hygiene.

[31]  F. Guirakhoo,et al.  Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All , 2006, Human vaccines.

[32]  J. Mendez-Galvan,et al.  The growing burden of dengue in Latin America. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[33]  A. Rothman,et al.  Understanding the contribution of cellular immunity to dengue disease pathogenesis , 2008, Immunological reviews.

[34]  M. Accavitti-Loper,et al.  Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. , 2009, Virology.

[35]  A. Nisalak,et al.  Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. , 2006, The Journal of infectious diseases.

[36]  J. Smit,et al.  Immature Dengue Virus: A Veiled Pathogen? , 2010, PLoS pathogens.

[37]  Immunogenicity of sanofi pasteur tetravalent dengue vaccine. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[38]  Soila Sukupolvi-Petty,et al.  Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3 , 2010, Journal of Virology.

[39]  Aidan McDermott,et al.  The Impact of the Demographic Transition on Dengue in Thailand: Insights from a Statistical Analysis and Mathematical Modeling , 2009, PLoS medicine.

[40]  N. Lennon,et al.  Emergence of the Asian 1 Genotype of Dengue Virus Serotype 2 in Viet Nam: In Vivo Fitness Advantage and Lineage Replacement in South-East Asia , 2010, PLoS neglected tropical diseases.

[41]  C. Huang,et al.  Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development , 2003, Journal of Virology.

[42]  D. Gubler,et al.  Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. , 2009, Cadernos de saude publica.

[43]  Alfonso Gúzman,et al.  Update on the global spread of dengue. , 2010, International journal of antimicrobial agents.

[44]  B. Guy,et al.  Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. , 2010, Vaccine.

[45]  A. Nisalak,et al.  Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study , 2007, The Lancet.

[46]  S. Halstead,et al.  Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. , 2009, The American journal of tropical medicine and hygiene.

[47]  B. Murphy,et al.  Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. , 2008, The American journal of tropical medicine and hygiene.

[48]  A. Nisalak,et al.  Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. , 2005, The American journal of tropical medicine and hygiene.

[49]  B. Murphy,et al.  Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1 , 2007, Virology Journal.

[50]  A. Nisalak,et al.  Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. , 2008, The American journal of tropical medicine and hygiene.

[51]  A. Nisalak,et al.  Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. , 2002, The Journal of infectious diseases.

[52]  M. Diamond,et al.  Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification , 2010, PLoS pathogens.

[53]  Ralph S. Baric,et al.  Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses , 2010, PLoS pathogens.

[54]  J. Smit,et al.  Functional importance of dengue virus maturation: infectious properties of immature virions. , 2008, The Journal of general virology.

[55]  J. Lang,et al.  A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. , 2010, The Journal of infectious diseases.

[56]  C. Stratton,et al.  Sensitive, qualitative detection of human herpesvirus-6 and simultaneous differentiation of variants A and B. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[57]  K. Porter,et al.  Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. , 2011, Vaccine.

[58]  B. Guy,et al.  Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. , 2008, Vaccine.

[59]  G. Chang,et al.  Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II , 2008, Journal of Virology.

[60]  J. Lang,et al.  Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. , 2006, Vaccine.

[61]  Steven A. Ogata,et al.  Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. , 2010, Vaccine.

[62]  Mario Recker,et al.  Immunological serotype interactions and their effect on the epidemiological pattern of dengue , 2009, Proceedings of the Royal Society B: Biological Sciences.

[63]  J. Farrar,et al.  Changing Patterns of Dengue Epidemiology and Implications for Clinical Management and Vaccines , 2009, PLoS medicine.

[64]  A. Rothman,et al.  Dengue immune response: low affinity, high febrility , 2003, Nature Medicine.

[65]  Derek A. T. Cummings,et al.  Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006 , 2010, PLoS neglected tropical diseases.